Integrating smoking cessation treatment into primary care: an effectiveness study

Fiore, Michael C.; McCarthy, Danielle E.; Jackson, Thomas C.; Zehner, Mark; Jorenby, Douglas E.; Mielke, Michelle M.; Smith, Stevens S.; Guiliani, Teresa A; Baker, Timothy B.

doi:10.1016/j.ypmed.2003.11.002

Cited by 83 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Attendance at the first session of the cessation programme increased to 11.3%, compared with 0.006% in a control group who received brief advice only. Fiore et al 28 also showed that many primary care patients identified as smokers will accept treatment 'if it is free, appropriately incorporated into the health-care delivery system to ensure convenience, and encouraged through proactive recruitment'.…”

Section: Lichtenstein and Hollismentioning

confidence: 99%

Start2quit: a randomised clinical controlled trial to evaluate the effectiveness and cost-effectiveness of using personal tailored risk information and taster sessions to increase the uptake of the NHS Stop Smoking Services

Gilbert

Sutton

Morris

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 08/58/02. The contractual start date was in June 2010. The draft report began editorial review in December 2015 and was accepted for publication in June 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. © Queen's Printer a...

show abstract

Section: Lichtenstein and Hollismentioning

confidence: 99%

Start2quit: a randomised clinical controlled trial to evaluate the effectiveness and cost-effectiveness of using personal tailored risk information and taster sessions to increase the uptake of the NHS Stop Smoking Services

Gilbert

Sutton

Morris

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…The recent success of the English smoking cessation services [103] has been based largely on the willingness of large numbers of smokers (over 500 000 per year) to attend for face-toface treatment. A recent US study [104] found that 68% of smokers in primary care expressed an interest in receiving treatment and 78% of eligible patients enrolled. The smokers in these US primary care practices were given the option of (a) a free course of nicotine patches; (b) the patches plus access to a telephone assessment and individualised supportive mailings; or (c) b plus face-to-face counselling at the family practice.…”

Section: Can Improved Psychosocial Treatments Enhance Pharmacotherapymentioning

confidence: 99%

Developments in pharmacotherapy for tobacco dependence: past, present and future

Foulds

Steinberg

Williams

et al. 2006

Drug and Alcohol Review

View full text Add to dashboard Cite

In the mid-1970s there were no effective pharmacological treatments for tobacco dependence. The invention of nicotine gum was a major treatment advance and also greatly helped our understanding of the nature of tobacco dependence. There are now eight effective pharmacotherapies (nicotine gum, patch, nasal spray, inhaler, lozenge/tablet, bupropion, nortriptyline and clonidine) available to aid smoking cessation. Other non-nicotine agents that show promise are under investigation, including glucose, rimonabant, selegiline and varenicline. Greater knowledge of the mechanisms of action of the effective non-nicotine agents should lead to better understanding of the nature of tobacco dependence. Future research into optimal treatments should examine long-term combination pharmacotherapy combined with improved psychosocial support that is partly designed to enhance medication compliance. In addition, there is a need for studies designed to evaluate the efficacy of pharmacotherapies in populations such as youth, pregnant smokers and smokers with co-occurring mental health problems.

show abstract

“…der «Sicherheit, auf das Rauchen verzichten zu können» (Mann-Whitney-U-Test, Z = -1,971; p = 0,049) zeigte sich bei der «Sicherheit, auf das Rauchen verzichten zu können» ein signifikanter Unterschied zwischen den beiden Gruppen (Mittelwert = 24,25; SD = 9,41 vs. Mittelwert = 18,74; SD = 6,56). [Fiore et al, 2004]. Insbesondere zeigen unsere Daten, dass auch bei Rauchern mit komorbider Alkoholabhängig-keit eine hohe Akzeptanz für KBGT im Rahmen von stationären, qualifizierten Entzugsbehandlungen besteht.…”

Section: Anzahl Der Besuchten Kbgt Und Deren Einfluss Auf Das Ergebniunclassified

Tabakentwöhnung mit kognitiv-behavioraler Gruppentherapie während einer 3-wöchigen qualifizierten Alkoholentzugsbehandlung: Effekte auf den Tabakkonsum

et al. 2018

View full text Add to dashboard Cite

Hintergrund: Überprüft wurde der Effekt einer kognitiv-behavioralen Gruppentherapie (KBGT) im Rahmen eines Tabakentwöhnungsprogramms auf die Tabakkonsumreduktion und -abstinenz während einer 3-wöchigen stationären, qualifizierten Alkoholentzugsbehandlung. Teilnehmer und Methoden: Von den 73 eingeschlossenen alkoholabhängigen Rauchern mit Rauchabstinenzmotivation entschieden sich 60 Probanden (82,2%) für ein Tabakentwöhnungsprogramm mit KBGT und Tabakentwöhnungsmitteln. 13 Probanden (17,8%), die eine alleinige Therapie mit Tabakentwöhnungsmitteln erhielten, bildeten die Kontrollgruppe. Ergebnisse: Im Vergleich zum Studieneinschluss konnten Probanden mit KBGT ihren durchschnittlichen Tabakkonsum zum Entlassungszeitpunkt und beim Follow-up nach 3 Monaten signifikant reduzieren. Probanden ohne KBGT schafften dies nicht. Zu den beiden Messzeitpunkten erreichten 28,3 bzw. 14,3% der Probanden mit KBGT eine Tabakabstinenz; bei den Teilnehmern ohne KBGT waren es 15,4 bzw. 9,1%. Dieser Unterschied erreichte jedoch keine statistische Signifikanz. Probanden, die zum Entlassungszeitpunkt und zum Follow-up tabakabstinent waren, hatten signifikant häufiger an den KBGT-Sitzungen teilgenommen. Mehr als zwei Drittel der tabakabstinenten Probanden hatten innerhalb von 7 Tagen nach Studieneinschluss einen Rauchstopp erreicht; 92,9% dieser Probanden waren Teilnehmer der KBGT-Gruppe. Schlussfolgerung: Die Bereitschaft zur Teilnahme an einer freiwilligen KBGT war hoch. Dabei zeigten sich signifikant bessere Reduktionsraten und nicht signifikant verbesserte Tabakabstinenzraten bei der Entlassung und im Follow-up. Die Ergebnisse weisen auf einen positiven Zusammenhang zwischen der Tabakabstinenzrate und einem frühzeitigen Rauchstopp bzw. einer höheren Anzahl an besuchten KBGT-Sitzungen bei Rauchern im Rahmen einer stationären Alkoholentzugsbehandlung hin.

show abstract

Integrating smoking cessation treatment into primary care: an effectiveness study

Cited by 83 publications

References 25 publications

Start2quit: a randomised clinical controlled trial to evaluate the effectiveness and cost-effectiveness of using personal tailored risk information and taster sessions to increase the uptake of the NHS Stop Smoking Services

Start2quit: a randomised clinical controlled trial to evaluate the effectiveness and cost-effectiveness of using personal tailored risk information and taster sessions to increase the uptake of the NHS Stop Smoking Services

Developments in pharmacotherapy for tobacco dependence: past, present and future

Tabakentwöhnung mit kognitiv-behavioraler Gruppentherapie während einer 3-wöchigen qualifizierten Alkoholentzugsbehandlung: Effekte auf den Tabakkonsum

Contact Info

Product

Resources

About